Development of agents to target oncogenes and the intracellular signalling pathways in which their products participate is already underway (Lemoine, 1992) . Inhibitors of tyrosine and serine/threonine kinases, inhibitors of growth factor receptor binding, and agents acting on phospholipid metabolism have all received attention (for reviews see Gullick, 1990; Grunick, 1991 The potential for targeting processes in transcription and translation through antisense technology stems from the specificity conferred by nucleic acid base-pairing. It might be easier to design a nucleic acid-based drug than drugs targeting proteins simply because nucleic acids are less structurally complex. A further perceived advantage of nucleic acid-based targeting is that by intervention at an earlier stage of gene expression, a more efficient drug (on a comparative molar basis) will result. This review seeks to highlight some of the approaches now being explored and the difficulties which must be overcome before antisense agents become a practical proposition for cancer therapy.
The antisense strategy
In principle the use of an antisense agent is exceedingly simple. The major premise is the potential precise targeting afforded by strand hybridisation. The shortest sequence which is likely to be unique within the mRNA pool of a human cell is on average 13 bases and within DNA 17 bases (discussed in more detail later). It is generally assumed that only a perfect match between the antisense agent and its target will lead to inactivation of the target. Although there is both theoretical (Herschlag, 1991) and experimental (Woolfe et al., 1992) evidence that this may not always be the case, there is evidence that the broad principle of antisense inhibition of gene expression is valid.
With the goal of selective inhibition of gene expression, there are a number of strategies in which antisense agents might be employed. The most obvious is the binding of an antisense agent to a target RNA molecule, either the cytoplasmic mRNA, or its nuclear localised precursor, hnRNA. The latter may have particular advantages over mature cytoplasmic mRNA. First, the hnRNA pool size is likely to be much smaller than that of cytoplasmic mRNA, consequently the intracellular concentration of the antisense agent required to block expression may be significantly lower. Second, attacking intron-exon junctions may afford a higher degree of gene specificity. However, the approach which has undoubtedly received most Cohen, 1991) . In the context of cancer, novel sequences are generated from within the cell by mutational processes such as chromosomal translocation or rearrangement. In a number of cases such mutations are known to produce novel fusion proteins with transforming properties (for instance, p2IOtbcr/abl). Mutational processes which result in single point mutations can lead to activation of some protooncogenes producing dominantly acting, transforming alleles (for instance, ras oncogenes).
Detailed knowledge of the sequence rearrangements which occur offers an opportunity to design antisense agents to block the expression of the aberrant new allele. Examples of this would include t(9;22) (the Ph chromosome), which gives rise to the fusion gene bcr-abl in chronic myelogenous leu-kaemia and in some forms of acute lymphocytic leukaemia. Based on the work of Szczylik et al. (1991) Dolnick (1991) has termed 'host-directed' targets. Examples would include down-modulation of the MDRI gene increasing the sensitivity of the target tissue to conventional cytotoxic drugs. Alternatively, suppression of enzymes for drug activation selectively in normal tissues cpuld allow increased doses of cytotoxics to be given for the tumour. One study has shown that antisense-mediated down-modulation of c-rafl mRNA, can lead to enhanced radiation-sensitivity and reduced tumorigenicity in a radiation-resistant human squamous carcinoma cell line (Kasid et al., 1989) . Similarly, in ovarian carcinoma cell lines a ribozyme targeting c-fos mRNA caused potentially useful pleiotropic effects such as reduced expression of DNA polymerase, and increased sensitivity to cisplatin (Scanlon et al., 1991) .
Types of agent currently under evaluation
Antisense and anti-gene agents currently under test are single-stranded oligodeoxynucleotides and chiefly their methylphosphonate, phosphorothioate and x-oligodeoxynucleotide analogues. The structures of these common forms are shown in Figure 1 . Other analogues are undergoing development, and indeed an approach under intense investigation is the design of non-nucleotide synthetic structures which mimic nucleic acids, so called 'plastic DNA' (Uhlmann & Peyman, 1990) . Novel oligodeoxynucleotide analogues in which the phosphodiester backbone is replaced with a polyamide (peptide nucleic acids, PNAs) look particularly promising (Nielsen et al., 1991; Hanvey et al., 1992) .
A basic principle in the design of antisense molecules is to achieve a balance between conferring sufficient specificity to the target sequence and maintaining useful physio-chemical properties to ensure cell penetration and maintenance of adequate concentration for the desired biological activity. Despite the apparently minor structural differences between the various analogues, clear differences in their activities can be shown.
The unmodified phosphodiester oligodeoxynucleotides are fairly readily taken up by cells and are relatively non-toxic in cell types tested so far. They are very efficient at hybrid formation and induce RNAse H activity (see later) in heteroduplexes with RNA. The major disadvantage of the unmodified oligodeoxynucleotides is their extreme sensitivity to degradation by cellular and extracellular nucleases. Their half-life in serum is limited to a few hours, and under some conditions can be as little as 15min.
The methylphosphonate oligodeoxynucleotides are less soluble than the phosphodiester linkage oligodeoxynucleotides and the other common analogues, but they have relatively good cell uptake characteristics with low toxicity and high stability. The major disadvantage of this class of analogue is relatively poor hybridisation efficiency and inability to induce the activity of RNase H.
The phosphorothioate oligodeoxynucleotides would seem to have properties which combine the best features of the unmodified and methylphosphonate oligodeoxynucleotides; good solubility, hybridisation efficacy, RNase H induction, and nuclease resistance. However, they appear to show sequence non-specific toxicity in some systems, and are also less well taken up by cells. Sequence-independent toxicity may be mediated by competitive inhibition of DNA polymerase a and P, and non-competitive inhibition of the -y and a polymerase (Gao et al., 1992) . The inhibitory effects appear to be related to the total number of thioate linkages and not the position of the linkages within the chain. Low concentrations of phosphorothioate enhance RNase H cleavage whereas at concentrations exceeding that of the target RNA RNase H is inhibited, protecting the complementary RNA from degradation (Gao et al., 1992) .
The fourth major type of oligodeoxynucleotide are the a-oligodeoxynucleotides. In these, the linkage formed by the deoxyribose with the purine or pyrimidine base in normal phosphodiester linkages is in the unnatural a position. Such a-oligodeoxynucleotides form parallel rather than anti- parallel duplexes with complementary DNA or RNA strands. These analogues show good solubility and stability. They are able to hybridise at least as efficiently as the phosphorothioates, but they do not induce RNAse H.
Some workers have exploited 'conjugated' oligodeoxynucleotides, i.e. those with particular reactive groups added to either the 5' or 3' end. The addition of such moieties to normal phosphodiester oligodeoxynucleotides to some extent stabilises them against nuclease attack. Such appendages may also improve cellular uptake if they are hydrophobic. Fluorescent groups provide markers for uptake and localisation, or can stabilise hybrid formation by intercalation with a double-stranded target sequence. Some of the conjugates can be catalytic centres, promoting strand cleavage at a specific target. Although such functionalisation is usually at the expense of Tm or sequence specific recognition, such approaches have seen particular application in anti-gene strategies.
An important factor to be considered in the use of some oligodeoxynucleotide analogues is stereoisomerism. This problem is raised once substitution at the internucleotide phosphate is achieved, and is a particular problem where relatively large substituents, such as the methyl group in the methylphosphonates, are introduced. Modification at n phosphodiester linkages will given given 2' iso-forms. Thus for a 15-mer (14 internucleotide linkages) there will be 32,568 stereoisomers. Not all isomers can bind their complementary target equally well. Some workers have used affinity purification to separate low from high affinity stereoisoforms of 9-mer methylphosphonates (Tidd et al., 1988) . Hybridisation experiments showed the Tm of the high and low affinity populations to differ by 7.6%.
Peptide nucleic acids are able to invade duplex DNA, causing displacement of one strand and the formation of a very stable 'D-loop' which blocks RNA polymerase II-mediated transcription. However, despite the advantage of high stability in serum and within the cell, there are significant problems to be overcome. These agents can bind DNA in either orientation (which increases the potential toxicity) and binding is relatively poor at physiological salt concentrations.
Ribozymes
A further class of antisense agent which merits consideration comprises the catalytic RNAs or ribozymes. Their structure and mode of action are entirely different to the systems we have described, but the outcome of their application and the kinds of target to which they might be directed are similar. Ribozymes are small oligo-ribo-nucleotides which have a specific base sequence with natural self-splicing activity. This activity can be directed against virtually any RNA target by the inclusion of an antisense region into the ribozyme, but at the moment there is still a need for a consensus GUC sequence in the target at the desired cleavage site. This, for instance, precludes being able to design ribozymes which can target many of the common ras gene mutations, but this situation may not always hold true. A PCR-based 'in vitro evolution' technique has been recently shown capable of producing a population of ribozymes with a 100-fold enhancement in target cleavage activity compared to the starting molecule (Beaudry & Joyce, 1992) . It may be possible to use such an approach to alter target specificity to suit any desired sequence. An example of a typical 'hammerhead' ribozyme is shown in Figure 2 .
A major disadvantage of ribozymes at present is that, being ribonucleic acids, they are particularly sensitive to nuclease degradation. Ribozymes are not generally being considered as agents which may be exogenously administered. Whilst it should be possible to develop nuclease-resistant ribonucleotide analogues, present strategies employing ribozymes achieve their delivery by genetic means, in the form of mini-gene constructs (Cameron & Jennings, 1989) . In one study (Cotten & Birnstiel, 1989) , the ribozyme RNA has been expressed in stablised form as a segment within a modified tRNA gene.
Anti-gene oligodeoxynucleotides, triple-helix agents
Oligodeoxynucleotides designed as anti-gene agents (those which target double-stranded DNA) are now usually referred to as 'triple-helix' formers or agents. It is usual for the oligodeoxynucleotide to be conjugated with a reactive group to provide a centre for specific strand cleavage, and also to stabilise and enhance hybridisation formation. Triple-helix formation is presently limited to homopurine-homopyrimidine sequences within the target DNA, and many important regulatory elements do not contain such sites. Moreover, third-strand binding is sensitive to physiological pH, requires protonated C residues (a pH effect) and is rapidly destabilised by transcription and DNA replication. The triple helix may also be susceptible to DNA repair processes within the cell. However, recent results have shown some relaxation in the target sequence requirements for third-strand binding. Some mixed sequence sites may be recognised by oligodeoxynucleotides in which G residues of the incoming third strand form stable base triplets with T-A base pairs on the target DNA. This has been shown to occur where the T residues interrupt a homopurine site (Griffin & Dervan, 1989) . Another approach using pyrimidine oligodeoxynucleotides linked at their 3' termini has shown that adjacent homopurine sites on opposite DNA strands can be successfully targeted (Horne & Duervan, 1990 Inhibitory activity of antisense molecules which target the 5' untranslated region of the mRNA are also probably influenced by RNAse H, to augment the steric effects of blocking ribosome assembly or passage.
RNase H is an enzyme involved in DNA replication and as such it is likely to be widely and constitutively expressed. At the present time, its cellular and tissue distribution (particularly in tumour tissue) is not well known and may limit therapeutic approaches based on this mechanism.
A major potential source of toxic side effects with antisense agents will result from fortuitous hybridisation with nontarget RNAs. It has been estimated that the oligodeoxynucleotide length required to specify a unique sequence of human mRNA is 11 nucleotides if the target contains only G and C residues, and 15 nucleotides for targets containing only A and T (Helene & Toulme, 1989) . Hence the average shortest unique sequence in the mRNA pool is 13 bases. There is evidence that a single internal mismatch within a 13-mer will not prevent degradation, indeed Woolfe et al. (1992) have shown that a complementary sequence of ten consecutive bases is sufficient to produce antisense degradation in a Xenopus oocyte system. Any given 1 3-mer will contain four different internal 10-mers and so could recognise any many as 76 different complementary sites. Longer oligomers will contain more internal 10-mers, and since flanking sequences do not prevent antisense effects (Woolfe et 3' al., 1992) , increasing the length of an oligomer is likely to increase rather than decrease the number of RNAs that will suffer non-specific degradation. However (Goodchild et al., 1988) . Successful and specific inhibition of oncogene expression and tumour cell growth has been reported with antisense oligodeoxynucleotides against the message for c-myc (Wickstrom et al., 1988; Holt et al., 1988) , c-myb (Gewirtz & Calabretta, 1988) , PCNA cyclin (Jaskulski et al., 1988) , retinoic acid receptor a (Cope & Wille, 1989 ) and c-fos using a ribozyme approach (Scanlon et al., 1991) . The p120 nucleolar antigen expressed in most human malignant tumours, and of some prognostic significance in breast cancer, has been inhibited to biological effect by a genetic antisense approach (Perlaky et al., 1992) .
Examples of antisense inhibition of autocrine stimulation loops have also been produced. Agents targeted to CSFI and its receptor c-fms can inhibit cell proliferation (BirchenallRoberts et al., 1990; Wu et al., 1990) . Similarly, antisense inhibition has been reported for interleukins 2, 4 and 6 (Harel-Bellan et al., 1988; Schwab et al., 1991) , EGF receptor (Moroni et al., 1992) and basic fibroblast growth factor (Murphy et at., 1992) .
It may be significant that in most of these cases the half-life of the mRNA is less than an hour and that complete loss of mRNA translation was not achieved, nor seemingly required, for a biological effect to be scored.
In the case of the ras family of proto-oncogenes, where the turnover of the protein product and its mRNA is comparatively slow, biological effects have also been noted. All three ras genes have been targeted by antisense approaches. N-ras has been down-modulated in haemopoietic cells in vitro (Skorski et al., 1992) . Ki-ras has been targeted using a genetic antisense approach (Mukhopadhyay et al., 1991) in which a human lung cancer cell line containing a homozygous Ki-ras mutation was engineered to express a Ki-ras antisense cDNA. Cells remained viable, but showed a 3-fold reduction in growth rate and concomitant reduction in tumorigenicity.
The Ha-ras gene has seen the most experimental attention, targeted by various antisense oligodeoxynucleotide analogues (Brown et al., 1989; Daaka & Wickstrom, 1990; Chang et al., 1991) , and in some studies by ribozymes (Kashani-Sabet et al., 1992; Koizumi et al., 1992) . A remarkably high degree of specificity was achieved for mutant-specific antisense oligodeoxynucleotides using a cell-free system targeting Ha-ras (Saison-Behmoaras et al., 1991) . The 9-mers used in this study were linked to an intercalating agent (5'-acridine) and/ or a hydrophobic tail (3'-dodecanol (Brown et al., 1989; Daake & Wickstrom, 1990; Chang et al., 1991) .
For all of these studies, including the genetic antisense inhibition of Ki-ras (Mukhopadhyay et al., 1991) (Agrawal et al., 1992; Zon, 1989) , and preliminary toxicological studies have shown that a dose of 100 mg kg-' body weight of phosphorothioate oligodeoxynucleotide for 14 days is non-toxic in mice. In most tissues the oligodeoxynucleotide was quite stable, but in liver and kidney there was apparent extension of the synthetic molecule. Much of the administered dose is excreted in the urine over 2 or 3 days (more rapidly for oligodeoxynucleotides with phosphodiester linkages) and very little in the faeces.
Oligodeoxynucleotides are undoubtedly able to enter living cells. However there is evidence that much of the material remains sequestered in the extracellular environment of an endosome. It is probable that a combination of mechanisms lead to uptake, including endocytosis, and receptor-mediated internalisation. The presence of hydrophobic moieties linked to the 5' or 3' end of an oligodeoxynucleotide can greatly influence the rate of uptake into the cell and its intracellular distribution. One recent study (Boutorine et al., 1992) showed that the addition of a porphyrin to the terminal phosphate of a 17-mer caused a 6-fold increase in uptake into T24 cells, while a 30-100 fold increase was achieved by addition of cholesterol to the oligodeoxynucleotide. On the down-side however, addition of cholesterol onto the oligodeoxynucleotide will dramatically reduce the Tm of the molecule.
The idea of including a terminal modification to enhance uptake has been taken a stage further by the report of successful delivery of antisense c-myb oligodeoxynucleotides to HL60 leukaemia cells, via receptor-mediated uptake. In this study (Citro et al., 1992 ) the oligodeoxynucleotide was linked to a transferrin/polylysine complex. In studies of cellular uptake, it is important to show that the internalised oligodeoxynucleotide is intact. As has been pointed out by Tidd (1990) , a particular difficulty when using oligodeoxynucleotides which have been 32P end-labelled is the removal of label by phosphomonoesterase and incorporation of the radioactivity into cellular pools. Difficulties can also arise when using fluorescent labels as reporter groups. Tidd (1990) has suggested that certain results Loke et al., 1988; 1989) using flow cytometry to follow a 5' acridine label can be explained on the basis of degradative mechanisms preceding uptake. Labelling of phosphorothioate oligodeoxynucleotides with 35S has proved effective in vitro (Agrawal et al., 1992) .
The subsequent distribution of the oligodeoxynucleotide within the cell may lead to loss of activity, for example if the molecule is locked inside endosomal vesicles. Some studies have been carried out on the effectiveness of using lipofusion as a method for introducing oligodeoxynucleotides into the cytoplasm. Not only does this method allow for the delivery of larger and/or modified oligodeoxynucleotides, it also protects the agent from extracellular degradation. However, liposome contents are primarily delivered to endosome/lysosome compartments where their contents are subjected to enzymatic degradation. Use of pH-sensitivie liposomes which release their contents following acid pH-induced fusion may circumvent this problem. Such vesicles can be made to provide receptor-mediated endocytosis and effective cytoplasmic release (Conner & Huang, 1986) . Loke et al. (1988) have used liposome fusion to deliver antisense phosphorothioate oligodeoxynucleotides to haemopoietic cells growing in culture. In these experiments c-myc mRNA was targeted resulting in reduction in c-myc protein level, a reduced rate of DNA synthesis and growth inhibition.
There is an increasing optimism that antisense molecules could be delivered as genetic antisense agents, carried and expressed by engineered retroviruses, or delivered by transfection in vitro into cells which are re-infused into the patient. To date 15 clinical trials employing retroviral delivery systems have been approved in the USA (Miller, 1992) . Such vectors are highly efficient at delivering genes into dividing cells. Gutierrez et al. (1992) have outlined a number of conditional promoters which might be included in a construct to provide tissue-specific expression of any gene or anti-gene vectored into a cell which is expressing the appropriate transcription machinery. Examples of such promoters include tyrosinase for melanoma, prostate-specific antigen for prostatic disease, polymorphic epithelial mucin for breast and pancreatic cancers. Much work remains to be done before such systems become suitable for clinical use.
Concerns and conclusions
There are important reservations to be addressed before we can say that antisense reagents really offer useful new therapeutic opportunities. If we examine some of the above mentioned effects, aside from establishing the principle that antisense strategies can work in certain highly controlled (and carefully chosen) model systems, is there really any prospect that a new therapeutic principle has been established? Clearly biological responses in terms of 'reduced proliferation', or differentiation have undoubtedly been shown. However, with a few exceptions, virtually no studies provide direct evidence that sequence-specific recognition by the oligodeoxynucleotide was responsible for the biological phenotype(s) observed. Also, what of the magnitude of the responses, are they significantly greater than those achievable with conventional approaches? There will be little advantage in gaining increased specificity with the new agents at the expense of poor efficacy. Questions of cost effectiveness cannot be addressed until scaled-up production of the appropriate agents has been achieved. We have little idea if these agents are likely to be immunogenic or toxic in long term administration. We would predict that the types of synthetic oligodeoxynucleotide in experimental use now are unlikely to be those which ultimately find clinical use. Other nucleic acid analogues, 'plastic-DNA', PNA and ribo-oligomers, all have potential advantages which need to be explored in vitro and in vivo. The genetic delivery of antisense technology by retroviruses and possibly minichromosomes or other systems looks set to make advances in the future.
We have paid some attention to the types of target that may be useful in ablating cancer cells. High prevalence of a given molecular lesion in a particular tumour may suggest it as a tempting target, but its ablation may be sufficient to destroy the cell. Much more basic information about both the disease and antisense technology itself is still required before we can offer new therapeutic agents for the treatment of cancer, but the signs are hopeful.
